

## **Product DataSheet**

## **Anti-Human HGF(Ficlatuzumab)**

Catalog #: B21505617

This product is for research use only and is not intended for diagnostic use.

## **Product Overview Lot Specific Information**

Volume: Lot Specific\*

Product Concentration: Lot Specific\*

Total Quality: Lot Specific\*

Indicates that this detail will be noted on the certificate of analysis that ships along with this product.

## **Product Information**

Target: HGF

Clone: Ficlatuzumab

Isotype: Human IgG1(K214R)-Kappa

Recommend Isotype Controls: Anti-HEL Human IgG1(K214R)-Kappa Isotype control

Expression System: CHO

Purity: > 95% as determined by SDS-PAGE

Endotoxin: <1EU/mg, determined by LAL gel clotting assay

Immunogen: N/A

Sterility: 0.2 µM filtered

Formulation: PBS, pH 7.4, contains no stabilizers or preservatives

Alternative Names: AV-299,SCH 900105;deafness, autosomal recessive 39; DFNB39; EC 3.4.21; EC 3.4.21.7; fibroblast-derived tumor cytotoxic factor; F-TCF; hepatocyte growth factor (hepapoietin A; scatter

factor); Hepatopoeitin-A; Hepatopoietin A; HGF; HGFB; HPTA; HPTAhepatocyte growth factor; lung fibroblast-

derived mitogen; Scatter factor; SF; SFhepatopoeitin-A

Recommended Dilution Buffer: ABDB-1002 or PBS, pH 7.4, Contains no stabilizers or preservatives.

Storage: 2 weeks, 2-8°C under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for a long-term storage.

Protocol Information: Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further



optimized experimentally in a dose response or titration experiment.